140 related articles for article (PubMed ID: 38063046)
1. Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Ruff SM; Stevens L; Bressler L; Khatri R; Sarna A; Ejaz AM; Dillhoff M; Pawlik TM; Rose K; Cloyd JM
J Surg Oncol; 2024 Mar; 129(4):775-784. PubMed ID: 38063046
[TBL] [Abstract][Full Text] [Related]
2. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Hamad A; Crossnohere N; Ejaz A; Tsung A; Pawlik TM; Sarna A; Santry H; Wills C; Cloyd JM
Pancreas; 2022 Jul; 51(6):657-662. PubMed ID: 36099500
[TBL] [Abstract][Full Text] [Related]
3. Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol.
Cloyd JM; Hyman S; Huwig T; Monsour C; Santry H; Wills C; Tsung A; Bridges JFP
Support Care Cancer; 2021 Jun; 29(6):3009-3016. PubMed ID: 33030596
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study.
Stevens L; Brown ZJ; Zeh R; Monsour C; Wells-Di Gregorio S; Santry H; Ejaz AM; Pawlik TM; Cloyd JM
World J Gastrointest Oncol; 2022 Jun; 14(6):1175-1186. PubMed ID: 35949220
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Quality of Online Information Regarding Neoadjuvant Therapy for Pancreatic Cancer.
Stevens L; Guo M; Brown ZJ; Ejaz A; Pawlik TM; Cloyd JM
J Gastrointest Cancer; 2023 Sep; 54(3):890-896. PubMed ID: 36327090
[TBL] [Abstract][Full Text] [Related]
6. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
7. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
8. Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer.
Hsu T; Nathwani N; Loscalzo M; Chung V; Chao J; Karanes C; Koczywas M; Forman S; Lim D; Siddiqi T; Stein A; Twardowski P; Nademanee A; Pal S; Siccion E; Hein M; Akiba C; Goldstein L; Smith D; Ma H; Feng T; Hurria A
J Am Geriatr Soc; 2019 May; 67(5):978-986. PubMed ID: 30901083
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.
Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J
Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
[TBL] [Abstract][Full Text] [Related]
11. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Schreiber L; Zeh R; Monsour C; Ejaz A; Tsung A; Pawlik TM; Miller E; Noonan A; Krishna SG; Santry H; Cloyd JM
HPB (Oxford); 2022 Jun; 24(6):833-840. PubMed ID: 34764009
[TBL] [Abstract][Full Text] [Related]
12. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.
Brown ZJ; Labiner HE; Shen C; Ejaz A; Pawlik TM; Cloyd JM
J Surg Oncol; 2022 Feb; 125(2):185-193. PubMed ID: 34599756
[TBL] [Abstract][Full Text] [Related]
13. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
16. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
18. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
19. Caregiver burden in Parkinson's disease: a mixed-methods study.
Geerlings AD; Kapelle WM; Sederel CJ; Tenison E; Wijngaards-Berenbroek H; Meinders MJ; Munneke M; Ben-Shlomo Y; Bloem BR; Darweesh SKL
BMC Med; 2023 Jul; 21(1):247. PubMed ID: 37424022
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
